NCT03666234 (PORTRAY) is a clinical trial in Idiopathic Pulmonary Fibrosis, sponsored by Dai Huaping.

Who is sponsoring NCT03666234?

NCT03666234 is sponsored by Dai Huaping.

What condition does NCT03666234 study?

NCT03666234 studies Idiopathic Pulmonary Fibrosis.

Is NCT03666234 still recruiting?

NCT03666234 is currently status unknown. Last updated 11 September 2018.

Last reviewed 2018-09-11 · How we verify

NCT03666234: PORTRAY

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Idiopathic Pulmonary Fibrosis Registry China Study

Status unknown Last updated 11 September 2018

What this trial tests

trial in Idiopathic Pulmonary Fibrosis in 800 participants. Status unknown.

Timeline

1 July 2018

Primary endpoint
30 June 2023

30 June 2023

Quick facts

Lead sponsor	Dai Huaping
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	800
Start date	1 July 2018
Primary completion	30 June 2023
Estimated completion	30 June 2023
Sites	1 location across China

Conditions studied

Idiopathic Pulmonary Fibrosis — all drugs for Idiopathic Pulmonary Fibrosis →

Sponsor

Dai Huaping

Who can join

40 and older, any sex, with Idiopathic Pulmonary Fibrosis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

By mean of registry of newly diagnosed Chinese IPF patients from more than 15 sites, this study aims to build IPF prospective cohort, set up normative clinical database and a biological specimen bank, and examine the clinical characteristics of newly diagnosed Chinese IPF patients, as well as the nature history, prognosis, comorbidities and complications of IPF patients in China, the current treatment pattern, burden of illness, and quality of life of Chinese IPF patients.

Publications & conference data

7 peer-reviewed publications reference this trial (live from Europe PMC):

Patient Registries in Idiopathic Pulmonary Fibrosis.
Culver DA, Behr J, Belperio JA, Corte TJ, et al · · 2019 · cited 39× · PMID 31034241 · DOI 10.1164/rccm.201902-0431ci
Idiopathic Pulmonary Fibrosis Registry China study (PORTRAY): protocol for a prospective, multicentre registry study.
Xie B, Ren Y, Geng J, He X, et al · · 2020 · cited 15× · PMID 33177132 · DOI 10.1136/bmjopen-2020-036809
Evaluation of respiratory muscle dysfunction in patients with idiopathic pulmonary fibrosis: a prospective observational study with magnetic resonance imaging.
Yang X, Wang H, Liu A, Ni Y, et al · · 2025 · cited 1× · PMID 40087606 · DOI 10.1186/s12890-025-03572-6
Basal Cells Contribute to Pulmonary Fibrosis via SP1‐Mediated Senescence‐Associated Secretory Phenotype
Wang X, Li Y, Zhao L, Zhang X, et al · · 2026
Quantitative label-free multiphoton imaging of collagen features predicts disease severity and progression in idiopathic pulmonary fibrosis.
Liu W, Sun Y, Zhao L, Wang S, et al · · 2026 · PMID 42135759 · DOI 10.1186/s12931-026-03714-2
Small airway lesions appear with the course of IPF and relate to the severity of pulmonary fibrosis progression.
Wang X, Zhao L, Song D, Zhang X, et al · · 2025 · PMID 41073982 · DOI 10.1186/s12890-025-03939-9
Small airway lesions appear with the course of IPF and relate to the severity of pulmonary fibrosis progression
wang x, Zhao L, Song D, Zhang X, et al · · 2025 · DOI 10.21203/rs.3.rs-6653847/v1

Verify or expand the search:

Other recruiting trials for Idiopathic Pulmonary Fibrosis

Currently open trials in the same condition.

NCT05988463 — Dose-Escalation Study of Artesunate Patients With IPF · Phase 1 · recruiting
NCT06241560 — A Study in People With Idiopathic Pulmonary Fibrosis to Test Whether Pirfenidone Influences the Amount of BI 1015550 in · Phase 2 · recruiting
NCT07407543 — A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SRN001 in Healthy Korean and Cauc · Phase 1 · recruiting
NCT07036523 — A Study to Find Out Whether BI 765423 Has an Effect on Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF) · Phase 2 · recruiting
NCT07225296 — A Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics o · Phase 1 · recruiting

Other Dai Huaping trials

Trials by the same sponsor.

NCT06655090 — Fibrotic Interstitial Lung Disease Early Recognition and Strategic Therapy Study in China · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03666234 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Dai Huaping
Last refreshed: 11 September 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03666234.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing